- Home
- NVT vs RDY Comparison
NVT vs RDY Comparison
Compare NVT & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVT
- RDY
- Stock Information
- Founded
- NVT 1903
- RDY 1984
- Country
- NVT United Kingdom
- RDY India
- Employees
- NVT N/A
- RDY N/A
- Industry
- NVT Industrial Machinery/Components
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- NVT Industrials
- RDY Health Care
- Exchange
- NVT Nasdaq
- RDY Nasdaq
- Market Cap
- NVT 11.5B
- RDY 12.1B
- IPO Year
- NVT N/A
- RDY N/A
- Fundamental
- Price
- NVT $88.00
- RDY $14.22
- Analyst Decision
- NVT Strong Buy
- RDY Strong Buy
- Analyst Count
- NVT 11
- RDY 2
- Target Price
- NVT $79.91
- RDY $16.95
- AVG Volume (30 Days)
- NVT 2.3M
- RDY 1.5M
- Earning Date
- NVT 08-01-2025
- RDY 07-23-2025
- Dividend Yield
- NVT 0.91%
- RDY 0.50%
- EPS Growth
- NVT 2.58
- RDY 2.20
- EPS
- NVT 3.51
- RDY 0.79
- Revenue
- NVT $3,306,600,000.00
- RDY $3,897,394,052.00
- Revenue This Year
- NVT $20.02
- RDY $7.61
- Revenue Next Year
- NVT $9.53
- RDY $1.89
- P/E Ratio
- NVT $57.43
- RDY $18.06
- Revenue Growth
- NVT 14.92
- RDY 15.86
- 52 Week Low
- NVT $41.71
- RDY $12.26
- 52 Week High
- NVT $92.75
- RDY $16.85
- Technical
- Relative Strength Index (RSI)
- NVT 63.59
- RDY 49.39
- Support Level
- NVT $89.00
- RDY $14.06
- Resistance Level
- NVT $92.75
- RDY $14.30
- Average True Range (ATR)
- NVT 2.61
- RDY 0.20
- MACD
- NVT 0.01
- RDY 0.05
- Stochastic Oscillator
- NVT 67.73
- RDY 58.44
About NVT nVent Electric plc
nVent is a leading global provider of electrical connection and protection solutions that touches a broad range of end markets including infrastructure, industrial, commercial, and residential. NVent designs, manufacturers, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.